Tenaya Therapeutics has announced the acceptance of multiple abstracts for presentation at the upcoming ASGCT Annual Meeting, including a late-breaking oral presentation of new clinical data from the RIDGE-1 Phase 1b/2 trial of TN-401, a gene replacement therapy targeting arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. This innovative therapy utilizes an AAV9 vector to deliver a functional PKP2 gene into heart muscle cells, addressing the root cause of this genetic condition, which affects approximately 70,000 individuals in the U.S. alone.

The significance of this development lies in TN-401’s potential to transform the treatment landscape for ARVC, a condition that currently relies on symptomatic management through medications and devices like implantable cardioverter-defibrillators (ICDs). The RIDGE-1 trial aims to evaluate both the safety and efficacy of a one-time intravenous infusion of TN-401, with new data to be presented detailing safety, biopsy, and efficacy outcomes from two dose cohorts. This could pave the way for a paradigm shift in how ARVC is treated, moving from palliative care to a more definitive, gene-based intervention.

The implications of these findings extend beyond ARVC treatment, as they may influence the broader field of gene therapy for cardiomyopathies. If successful, TN-401 could expedite the development timelines for similar gene therapies targeting other genetic heart diseases, including Tenaya’s TN-501 for PLN-R14del-associated dilated cardiomyopathy. This could catalyze increased investment and research into gene therapies, ultimately enhancing the therapeutic options available for patients with genetic heart conditions.

Source: globenewswire.com